INTRODUCTION
Rutin (quercetin-3-O-rutinoside) is a naturally occurring flavonol glycoside widely distributed in fruits, vegetables, and medicinal plants. Increasing evidence suggests that rutin possesses anti-inflammatory and anti-allergic properties through modulation of oxidative stress and immune signaling pathways. This review aimed to critically evaluate the molecular mechanisms, pharmacological activities, and therapeutic potential of rutin in inflammatory and allergic disorders.
METHODS
A comprehensive literature search was conducted using PubMed, Scopus, Web of Science, and Google Scholar for studies published up to January 2025. Relevant in vitro, in vivo, and clinical studies investigating the anti-inflammatory and anti-allergic effects of rutin were selected according to predefined inclusion and exclusion criteria and systematically analyzed.
RESULTS
The reviewed studies demonstrated that rutin exerts anti-inflammatory effects by inhibiting Nuclear Factor-Kappa B (NF-κB) and Mitogen-Activated Protein Kinase (MAPK) signaling pathways, thereby reducing the production of pro-inflammatory mediators, including Tumor Necrosis Factor-Alpha (TNF-α), Interleukin-1 beta (IL-1β), and Interleukin-6 (IL-6). Rutin also activates the nuclear factor erythroid 2-related factor 2/Heme Oxygenase-1 (Nrf2/HO-1) pathway, enhancing antioxidant defenses and reducing oxidative stress. In allergic conditions, rutin stabilizes mast cells, suppresses histamine release, decreases Immunoglobulin E (IgE)-mediated responses, and modulates immune-cell activation.
DISCUSSION
Although substantial preclinical evidence supports the therapeutic potential of rutin, limitations such as poor bioavailability, variability among experimental studies, and limited clinical validation remain significant challenges.
CONCLUSION
Rutin exhibits promising anti-inflammatory and anti-allergic activities through multitarget modulation of inflammatory, oxidative stress, and immune pathways. Further well-designed clinical studies and advanced drug-delivery strategies are required to facilitate its translation into clinical practice.
R. Mishra, J. K. Gupta, Vinay Jain· Anti-Inflammatory & Anti-All...· 0 citations
BACKGROUND
The effects of Alzheimer's disease (AD) on society are profound. The blood-brain barrier selectively permits the penetration of specific forms of molecules through the blood circulation into the CNS, which can restrict the effectiveness of medications supplied systemically. The therapeutic targets are located in the CNS. However, local administration channels to the CNS are rather intrusive, which can lead to patient discomfort and limit the feasibility of repeated treatments.
METHODOLOGY
This article has evaluated treatment methodologies for AD that use nanoparticles to target the brain and the pathological features of the illness. The material that is currently available has been categorized based on the aspect of AD that is discussed: targeted medication and neurodegeneration.
RESULT
The use of nanoparticles in the targeted delivery of medications intended to alleviate the symptoms of AD or halt the disease's progression has yielded positive results. Because of their multivalence, nanoparticles can target the treatment site, pass through the blood-brain barrier, and be functionalized with various targeting groups. Intravenous administration, rather than more intrusive techniques, has enhanced drug bioavailability in the CNS. Furthermore, the development of vaccinations and medication formulations for intranasal delivery has utilized nanoparticles.
DISCUSSION
This study focused on the advancement of AD treatment. Nanoparticles are designed to enhance drug bioavailability through intravenous and intranasal routes for quicker brain access with fewer side effects. Nanoparticles also aid in targeting disease features like amyloid- beta plaques and tau tangles. While results in animal models are positive, transitioning to human clinical trials requires a more profound understanding of AD mechanisms and biomarker identification.
CONCLUSION
Research employing animal models suggests that targeted nanoparticles can enhance the effectiveness of AD treatments. A deeper understanding of AD mechanisms will lead to more successful targeted nanoparticle applications.
R. Mishra, Nidhi Chauhan, K. K. Agrawal· Current Neurovascular Resear...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.